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Summary 
The Human Toxicology Project Consortium (HTPC) was created to accelerate implementation of the science and policies 
required to achieve a pathway-based foundation for toxicology as articulated in the 2007 National Research Council report , 
Toxicity Testing in the 21st Century: a Vision and a Strategy. The HTPC held a workshop , “Building Shared Experience to 
Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action,” in January, 2013, in Baltimore, 
MD, to further the science of pathway-based approaches to liver toxicity. This review was initiated as a thought-starter for this 
workshop and has since been updated to include insights from the workshop and other activities occurring in 2013. The report of 
the workshop has been published elsewhere in this journal (Willett et al., 2014). 
 
 
 
 
1 History of pathway-based approaches to toxicology 
 
1.1 Introduction 
Experience over several decades of characterizing chemical toxicity has led to the realization that a new approach is warranted. 
Such factors as the large number of relatively uncharacterized chemicals that are already in the environment, the need to generate 
information for extensive regulatory programs such as the European Union’s Registration, Evaluation, Authorization and 
Restriction of Chemical substances (REACH) program, the high cost and slow pace of animal experimentation and the need to 
improve the certainty of safety decisions have made it necessary to rethink the traditional approach to hazard and risk assessment, 
which has generally relied on an extensive array of empirical animal test data (Bradbury et al., 2004). These findings, combined 
with advances in biological understanding and in experimental technologies (e.g., ‘omics tools, stem cell culturing, reconstructed 
tissues), have allowed the contemplation of dramatically different approaches to toxicology than those traditionally practiced. One 
such approach couples existing knowledge of normal biology with new chemical and biological information about the 
consequences of disturbing that biology, leading to a structured, transparent, and hypothesis-based approach to toxicology. From 
this thinking the Mode-of-Action (MoA), Toxicity Pathway, and Adverse Outcome Pathway (AOP) approaches have evolved 
(Ankley et al., 2010; Boobis et al., 2008; NRC, 2007; US EPA, 2006). 
 
1.1.1 Pathway-based toxicology 
The idea of incorporating mechanistic biochemical information into toxicological assessment is not new; it began with dose-
response modeling efforts (for example, see Clewell et al., 1995) and mode-of-action frameworks, such as those developed by the 
International Program on Chemical Safety (IPCS) to determine human relevance of modes-of-action of pesticides and industrial 
chemicals leading to carcinogenic (Boobis et al., 2006) and non-carcinogenic (Boobis et al., 2008) toxicity, and the creation of 
mode-of-action pathways commonly used in drug development (e.g., Iorio et al., 2010) and applied to human disease (e.g., Schadt 
and Lum, 2006). These efforts were novel in applying mechanistic information about the chemical-bio-molecular interactions to 
the interpretation of complex empirical data. The notion of toxicity pathways as articulated by the National Research Council in 
2007 takes this concept a bit further by envisioning a system-wide network of pathways that leads to a predictive, hypothesis-
driven assessment paradigm for toxicity in general (NRC, 2007). In this iteration, the “toxicity pathway” consists of a series of 
well-described chemical and biological mechanistic steps at progressively higher levels of biological complexity, beginning with 
the initial perturbation (e.g., chemical exposure) and following through to the eventual biological result (the adverse outcome). 
This concept also critically includes the notion that adversity is only achieved when homeostasis has been overcome. Recently, 
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this concept has been further formalized for toxicological assessment for both human health and ecological endpoints as the 
Adverse Outcome Pathway (AOP) (Ankley et al., 2010). The Organization for Economic Cooperation and Develo pment (OECD) 
has become a driving force in the development and use of AOPs, initially as a mechanism for facilitating the grouping of 
chemicals within the OECD Toolbox that has developed into a fundamental organizing principle for test guideline development 
(OECD, 2011).2  
 
1.1.2 Mode-of-Action frameworks 
The IPCS cancer and non-cancer MoA frameworks outline a systematic process of describing chemical MoA in animals and 
comparing those with likely MoA in humans to determine human relevance (Meek et al., 2003). Several founding principles of 
pathway-based approaches are articulated in the original IPCS frameworks: MoA defined as a series of key events along a 
biological pathway from the initial chemical interaction through to the toxicological outcome; a recognition that a MoA does not 
need to be complete to be useful and that its use depends on level of completeness (e.g., incomplete MoA can inform testing 
strategies but is likely not sufficient to support hazard classification); a focus on a single MoA at a time while recognizing that a 
chemical may have more than one MoA and that several modes may be related; definition of a “key event” as a step in the 
pathway that is critical to development of the toxicological outcome and is measurable; a requirement to systematically establish 
causation between key events; the importance of establishing quantitative parameters in order to apply the MoA to risk 
assessment; and the need to establish relevance to human biology. In this context, mode-of-action is distinguished from 
mechanism of action: the latter being defined as a more detailed description of the pathway that includes molecular interactions. 
There is some disagreement between pathway based approaches on the definition of these terms, and this definition is one of at 
least two definitions of mode and mechanism of action (see Table 1 for a summary of pathway-related terms).  
 Establishing evidence for the MoA hypothesis is based on the Bradford-Hill criteria for establishing causation: strength 
of association, consistency of the evidence, specificity of the relationship, consistent temporal relationships, dose-response 
relationships, biological plausibility, coherence of the evidence, and consideration of alternative explanations (Bradford-Hill, 
1965). The IPCS frameworks recommend determining human relevance by answering four key questions: 1) is there sufficient 
weight-of-evidence for the MoA in animals? 2) can human relevance be excluded on the basis of qualitative differences in key 
events? 3) can human relevance be excluded on the basis of quantitative differences in key events? and 4) do the quantitative 
differences affect the default uncertainty factors applied in risk assessment?  
 The MOA framework has been updated to accommodate insights from the expanding application of pathway-based 
approaches to risk assessment in general (Meek et al., 2014). Similar to the AOP concept, the updated MOA framework more 
explicitly describes the contribution of information at different levels of biological complexity, for example by describing early 
key events as being more related to chemical characteristics (of the Molecular Initiating Event) and later key events as being less 
chemical-specific and more of a common expected consequence of earlier key events. In this framework, MoA and AOP are 
conceptually similar, with a distinction in that MoA does not necessarily imply adversity; it can also refer, for example, to 
efficacy of a drug (Tab. 1). The updated MoA framework also extends through to the adverse outcome (or therapeutic effect) – 
this was considered a distinction of AOPs in the 2010 Ankley paper. Two applications of the updated framework are presented; 
for observed (in vivo) effects and for hypothesized events, and case studies are presented for each, providing concrete examples of 
the integration of information, using modified Bradford-Hill criteria, to transparently document the level of confidence of 
information to support regulatory decisions. 
 MoA frameworks have been incorporated into toxicological assessment guidance by the US EPA and others (US EPA, 
2007; Carmichael et al., 2011). Some limitations to the use of this approach have been that traditional animal tests do not provide 
data to support MoA development or assessment, therefore, such assessment requires a fair amount of additional specialized 
animal experimentation as well as in vitro analyses. In addition, it is difficult to ascertain when enough information has been 
obtained for sufficient weight of evidence. Other barriers include a lack of harmonized terminology and assessment methods as 
well as human information for comparison (note, these issues pertain to all pathway based approaches at the moment) 
(Carmichael et al., 2011).  
 
1.1.3 Toxicity pathways and the NRC “Vision” 
In its, by now, seminal 2007 report Toxicity Testing for the 21st Century: a Vision and a Strategy, the National Research Council 
panel describes a “transformative paradigm shift” that “envisions a new toxicity-testing system that evaluates biologically 
significant perturbations in key toxicity pathways by using new methods in computational biology and a comprehensive array of 
in vitro tests based on human biology” (NRC, 2007). In this context, a “toxicity pathway” is a normal biological pathway that 
becomes perturbed beyond the point of homeostatic correction leading to toxicity. A description of toxicity begins with chemical 
characterization, progresses through elucidation of the chemical interaction with the biological system (the pathway), involves 
targeted testing to query effects at critical steps of the pathway, and dose-response extrapolation to estimate human exposures 
required to elicit the effect. Additional population-based modeling is required to predict ecological effects. The level of 
assessment required depends on the risk context (e.g., will the information be used for prioritization or for risk assessment?). 
 
1.1.4 The Adverse Outcome Pathway (AOP) approach 
A similar approach, the AOP approach, arose from the field of ecotoxicology (primarily at the International QSAR Foundation3 
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and the Mid-Continent Ecology Division of the EPA in Duluth, MN) as a way of addressing uncertainty in risk assessment for an 
increasing number of chemicals and endpoints – and as required by new legislation. As described by Ankley et al., an AOP is a 
flexible framework that can include linking relationships that are “causal, mechanistic, inferential, or correlation based, and the 
information on which they are based may derive from in vitro, in vivo, or computational systems” and can encompass both 
mechanism and mode-of-action (Ankley et al., 2010). An AOP describes the events that occur following chemical exposure, 
beginning with the molecular interaction of the chemical with a biomolecule (e.g., a protein, receptor, etc.) – the molecular 
initiating event (MIE) – followed by a description of the sequential cellular and tissue perturbations that lead to eventual 
toxicological effect – or adverse outcome – which is at the individual level for most human health endpoints or at the population 
level for environmental endpoints (Fig. 1). The AOP framework allows for the integration of all types of information at different 
levels of biological organization, from molecular to population level, to provide a rational, biologically based argument (or series 
of hypotheses) to predict the outcome of an initiating event. In this description, the AOP builds on the MoA concepts and includes 
the “toxicity pathways” as described in the 2007 NRC report.  
 The AOP concept is useful in developing a predictive toxicological framework in several ways. In the near-term, even 
incomplete AOPs can inform chemical grouping or categories and structure activity relationships, they can aid in increasing 
certainty of interpretation of both existing and new information, and they can be used to inform integrated testing strategies that 
maximize useful information gained from minimal testing (OECD, 2013). In the longer-term, as they become more completely 
described and quantitative information is added to the links between steps, AOPs can be used to identify intermediate or key 
events for which non-animal tests can be developed, thereby facilitating transparent, mechanism-based, predictive toxicological 
assessments with low uncertainty and high human relevance, and ultimately without the use of animals. As AOPs are developed, 
it is important to clearly identify its completeness, as that will determine its potential use applicability.  
 In 2009, the Society of Environmental Toxicology and Chemistry held a Pellston workshop on Predictive 
Ecotoxicology in the 21st Century that explored two main practical aspects of creating a pathway-based framework for regulatory 
decision making: linkage (linking observations a different levels of biological complexity to individual or population effects) and 
extrapolation (quantitative tool that can extrapolate cell- or tissue-level data to individuals or populations) (for an overview, see 
Villeneuve and Garcia-Reyero, 2011). AOPs serve the purpose of linking observations at all levels of biological complexity and 
can identify alternative endpoints for use in hazard assessment. During the Pellston workshop, two complementary approaches to 
AOP development were demonstrated by case examples: using domoic acid as a case study, an AOP was created from existing 
information in the literature (Watanabe et al., 2011); using disruption of the hypothalamus-pituitary-gonadal endocrine axis in 
fathead minnows as a case study, ‘omics data were used to reverse engineer pathways (Perkins et al., 2011). Two other 
publications from that workshop explore quantitative prediction models that begin to address consideration of the complexities of 
predicting outcomes at higher-level biological organization from information at relatively less complex levels, including 
homeostasis (Nichols et al., 2011), species differences (Celander et al., 2011) and extrapolation to population-level effects 
(Kramer et al., 2011).  
 
1.1.5 Organization for Economic Cooperation and Development (OECD) AOP Project 
The OECD held a Workshop on Using Mechanistic Information in Forming Chemical Categories in 2010, one of the first 
workshops to gather scientific expertise to guide further AOP development (OECD, 2011). The 2010 workshop focused on the 
use of AOPs in building chemical categories for read-across, how AOPs might be used in Approaches to Integrated Testing and 
Assessment (IATA) and in identifying Key Events. For the purposes of the Workshop, an AOP was defined as “a narrative which 
delineates the documented, plausible, and testable processes by which a chemical induces molecular perturbations and the 
associated biological responses which describe how the molecular perturbations cause effects at the subcellular, cellular, tissue, 
organ, whole animal and (if required) population levels of observation” (Tab. 1; OECD, 2011). Based on discussion of several 
case studies, AOPs were further defined as being based on a single, defined MIE that is linked to a specific in vivo hazard 
outcome. The workshop also discussed development of a template that would summarized all of the information supporting the 
AOP, including “1) the level of qualitative understanding of the AOP; 2) consistency of the experimental data; 3) confidence in 
the AOP, and 4) level of quantitative understanding of the AOP (OECD, 2011). 
Since the 2010 workshop, OECD has published guidance and a template for development that is currently undergoing 
further revision (OECD, 2013). The published Guidance includes a description of the elements and uses of AOPs, a glossary of 
terms, and a template for developing an AOP. The goals of this guidance are to provide consistency in structure and facilitate 
harmonized use of AOPs.  
According to the OECD Guidance, an AOP consists of three main elements: one molecular initiating event (Anchor 1), 
one Adverse Outcome (Anchor 2), and any number of intermediate events. While in reality an MIE can be associated with a 
number of adverse effects, and similarly an adverse effect can result from a number of different MIE, to streamline the 
development and use of AOPs, OECD has defined an AOP as being a linear pathway from one MIE to one adverse outcome. A 
full description of an MIE should include cellular/tissue location – as immediately elicited intermediate events may be similar in 
two different AOPs, but differ in cell-type or tissue location (for example, metabolic transformation of a chemical to an 
electrophilic species may occur in both skin sensitization and liver fibrosis – only in keratinocytes for the former and hepatocytes 
for the latter). In order for an intermediate event to be identified as a “key event,” it must be able to be evaluated experimentally 
and causally linked to the adverse outcome. A key event may be shared between two or more AOPs. The Guidance describes the 
process for evaluating weight-of-evidence for each step in development of an AOP. 
Similar to the IPCS MoA frameworks described above, the OECD guidance suggests evaluation following the 
Bradford-Hill principles. In addition, the guidance recommends evaluating the confidence in each element of the AOP, 
specifically to address the following: how well characterized are the MIE, adverse outcome, and each intermediate or key event? 
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What are the limitations of the evidence used to support the AOP? What are the specific parameters of the AOP (e.g., life stage, 
tissue, etc.)? To what degree are the AOP elements conserved across species?  
AOPs have a number of potential uses, including 1) supporting chemical category formation and “read-across” 
(predicting the toxicity of one chemical based on results from a related chemical), 2) priority setting for further testing, 3) hazard 
identification 4) classification and labeling, and 5) risk assessment. As use progresses from 1-5, a corresponding increase in the 
level of evidence and certainty is necessary for adequate confidence. An AOP can also form the basis for an integrated approach 
to testing and assessment (IATA) or an integrated testing strategy (ITS) that would be designed to increase the certainty of any 
decision made regarding a particular substance (OECD, 2013).  
There are currently more than 20 AOP projects in the OECD work plan, including pathways and case studies (an AOP 
that is related to one specific chemical).4 In addition, OECD is collaborating with the European Commission Joint Research 
Centre and the US EPA to develop the AOP Knowledge base (AOP KB; described in more detail in the next section).  
 
1.1.6 AOP Knowledge Base and related projects 
To develop a system of AOPs that covers the broad spectrum of biological pathways that are likely to be involved in human 
health and ecological risk assessment, it is necessary to create a unified knowledge base for AOPs and their supporting evidence 
that integrates information from all scientific sectors, including toxicology, drug development, disease, medicine and research. An 
Adverse Outcome Pathway Knowledge Base (AOP KB) is currently being developed by the OECD Extended Advisory Group on 
Molecular Screening and Toxicogenomics (EAG MST) and is being implemented by the European Commission's Joint Research 
Centre (JRC) and the US Environmental Protection Agency (US-EPA).2,5,6,7,8 The AOP KB is an IT system to capture, manage 
and share AOP information and will consist of three modules: 1) AOP-WIKI, a text-based tool allowing the management of AOP-
related knowledge (AOPs, Key Events, relationships between them) in a Wikipedia-like environment, 2) a graphical tool 
implementing quantitative models depicting the relationship between two events in an AOP (Effectopedia) and 3) an Intermediate 
Effects Database (AOP Network tool) to manage information about intermediate effects triggered by chemicals.  
The first available module, the AOP Wiki, leads AOP developers through the steps necessary to capture the scientific 
information needed to document an AOP – following and implementing OECD guidance on how to describe AOPs. The Wiki 
also provides a collaborative space for groups to develop AOPs independent of geography or organizational boundaries. Currently 
a beta version of the AOP Wiki is available only for OECD AOP development teams but the goal is to eventually make this 
publicly accessible with registration. 
 
1.2 Two example AOPs in development and use 
There are several examples of AOPs that are currently used to support decision-making in a number of research and regulatory 
contexts; the two examples provided below were among the first examples to be developed and were presented to on Using 
Mechanistic Information in Forming Chemical Categories (OECD, 2011). At this workshop, the skin sensitization AOP was 
presented as an example of using mechanistic information in forming categories how this information was used in the OECD 
Toolbox at that time. The AOP is currently also being used to support interpretation and design of integrated testing strategies that 
are being developed to replace animal testing, primarily in the cosmetics sector (but could have broader applicability; see EC, 
2013b). The estrogen receptor-mediated reproductive toxicity AOP was developed to support a QSAR-assisted decision tree for 
prioritizing largely inactive chemicals for ecological risk assessment and was presented as a case study at the workshop 
demonstrating the use of structural requirements for ER-binding, supported by other evidence from key events along the pathway, 
as a basis for read-across. The development of each of these pathways preceded the OECD guidance; however, both have been 
incorporated into the OECD Toolbox.  
 
1.2.1 Skin sensitization 
Skin sensitization is a relatively simple biological process yet involves several cell types and tissues and is a good demonstration 
of AOP development and use in constructing an integrated testing strategy (Fig. 2). Sensitization occurs in two phases: the first, 
the induction phase, is a result of initial contact with an allergen and primes the system; the second, the elicitation phase, is in 
response to a subsequent exposure and results in an allergic response. As with the Local Lymph Node Assay, the sensitization 
AOP focuses on the induction phase.  
Sensitization can occur via a few different molecular initiating events, such as reactivity with certain metals or 
reduction-oxidization cycling, this AOP describes sensitization occurring via the covalent modification of proteins on the cell 
surface of skin cells, specifically reactions of organic chemicals with thiols (e.g., on cysteine) and primary amines (e.g., lysine). 
Therefore the molecular initiating event is covalent reaction with proteins (OECD, 2012).  
The induction phase involves initial contact and penetration of the outer dermis of the skin by a potential sensitizer. 
Metabolism in the skin can either activate or deactivate the chemical (or have no effect); chemicals that are electrophilic after 
penetrating the skin are more potent sensitizers than non-electrophiles. The electrophile then interacts irreversibly with 
nucleophilic sites in proteins (e.g., cysteine and lysine residues) to form a hapten-protein complex in the epidermis – this is the 
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sensitization MIE. In both dendritic cells (antigen-processing cells in the skin) and keratinocytes (the predominant epidermal skin 
cells), the presence of a hapten-protein complex elicits the production of cytokines that in turn stimulate dendritic cells to migrate 
to regional lymph nodes and activate T cells there. In the lymph node, hapten-protein fragments are presented in complex with 
MHC molecules by dendritic cells to immature T cells, causing the maturation of memory T cells and the acquisition of sensitivity 
– this is the key physiologic response of the initiation phase.  
The summary of the scientific evidence supporting the AOP indicates that the MIE is very well supported and the key 
events are qualitatively well supported and therefore the AOP is appropriate for qualitative hazard identification; however, the 
measurements sufficient for determining potency have not yet been defined (OECD, 2012). The AOP is thought to be applicable 
generally for mammals without age or sex restriction.  
The sensitization AOP is being used to design and interpret integrated assessment strategies that include non-test (e.g., 
QSAR), in vitro and in vivo test results. Such assessment strategies are being developed by a number of research groups (OECD, 
2012; Aeby et al., 2010; Bauch et al., 2011; EU 7th Framework Programme Sens-it-iv9; Jaworska et al., 2011; Lambrechts et al., 
2010; Natsch et al., 2013; McKim et al., 2012). For example, Bauch et al. (2011) investigate the use of four assays, the direct 
peptide reactivity assay (DPRA), the KeratinoSense™ assay (a cell-based reporter gene assay for Nrf2 activity), and the dendritic 
cell activation assays using the cell lines U-937 cells (MUSST) and THP-1 cells (h-CLAT). The results of each assay were 
compared with both human and LLNA data, with overall accuracy for 23 substances between 83% and 91% compared to human 
patch test data and between 78% and 91% compared to LLNA data. The authors noted that a combination of the MUSST and 
KeratinoSens™ assays resulted in 100% accuracy for the 23 compounds and suggested verifying these results using a larger 
chemical set. As of this writing, the European Commission Joint Research Centre’s European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL-ECVAM) has recommended use of two assays, DRPA and KeratinoSens™ to support 
identification of sensitizers and non-sensitizers as well integrated strategies to assess potency according to GHS; it was noted, 
however, that such strategies remain to be identified (EC, 2013a, 2014). Research is ongoing to identify assays and integrated 
strategies that will allow potency assessment. 
 
1.2.2 Estrogen receptor-mediated reproductive toxicity 
This AOP was established to address EPA’s regulatory need to assess tens of thousands of chemicals and identify priority 
chemicals for further assessment and serves as the mechanistic basis for a QSAR-based Expert System for chemical prioritization 
(OECD, 2011; US EPA, 2012). The expert system was originally developed to cover two specific inventories of interest that are 
expected to be weak binders: food use pesticide inert ingredients (FI), and antimicrobial active ingredients (AM). 
Since a large percentage of estrogen-active compounds function through the estrogen receptor (ER) in a wide range of 
species, the MIE for this pathway is ER binding. Initiation of events by a chemical binding the estrogen receptor (ER) occur as a 
result of sufficient chemical uptake into the organism and partitioning to a target tissue with ER-containing cells followed by 
changes in expression levels of ER responsive genes. Subsequent changes in ER-responsive protein levels result in changes at the 
tissue level (e.g., reproductive organs) and eventually can affect reproductive behavior and capacity (Fig. 3) (OECD, 2011; 
Schmieder et al., 2004; US EPA, 2012). In this AOP description (based on measurements in rainbow trout with elements that are 
generalizable to all vertebrates), the MIE is chemical binding to the estrogen receptor, the first key event is change in gene 
expression and protein production (measured via ER-responsive reporters in vitro or endogenous genes ex vivo), a subsequent key 
event is histopathological changes (e.g., reduced testicular growth, appearance of ova in testes of fish) followed by observation of 
altered reproductive behavior and sex reversal at the individual level, and finally skewed sex ratios and decreased numbers at the 
population level.  
This AOP also provides a biological hypothesis framework for an integrated testing strategy that involves QSAR 
prediction and measurement of ER binding, measurement of ER transcriptional activity in cells and excised (liver) tissue, 
histology of sexual organs, and measurement of sexual behavior and fecundity (OECD, 2009).  
 
1.3 Examples of different approaches to pathway development 
The ongoing projects described below cover examples of different but complementary approaches to developing pathways and 
assays to support regulatory decisions. 
 
1.3.1 Pathways of Toxicity (PoT) and the Human Toxome 
The Johns Hopkins School of Public Health Center for Alternatives to Animal Testing (CAAT), along with partners from 
government and industry, was awarded a $6 million grant from the National Institutes of Health in 2011 in order to address of one 
these areas, namely mapping cellular pathways of toxicity (PoT) (Parsons, 2011). The complete complement of these pathways 
would comprise the “Human Toxome.” The PoT project is focusing on comprehensively mapping the pathways of endocrine 
disruption in human breast cancer cells as a first step in mapping the Human Toxome.  
A workshop on the Concept and Tools for Pathways of Toxicity was held in Baltimore on October 10-12, 2012.10 This 
workshop introduced the concept of Pathways of Toxicity, as being similar to the Toxicity Pathways described in the 2007 NRC 
report in that they cover the pathway from the molecular initiating event up through the first key events at the cellular response 
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level and not necessarily through to the adverse effect. PoT are informed to a greater degree by systems biology approaches than 
the Toxicity Pathways envisioned by the NRC report and can identify previously unknown pathways. This approach will 
complement AOP approaches based on existing and chemical-specific information. The workshop explored ways in which 
systems biology approaches, including toxicogenomics, proteomics and metabolomics could inform pathway development. Some 
interesting concepts that were discussed at the 2012 workshop included: 
– Systems (‘omics) approaches and large databases can be used to identify predictive signatures and can be combined together 
with carefully curated pathways derived from current biological understanding to form complementary approaches to 
pathway development. 
– The bounds of a “pathway” may be fluid over time. At present, the Adverse Outcome Pathway is conceptually bounded by a 
Molecular Initiating Event on one end and a single adverse outcome on the other; however, eventually these pathways will 
be extended to encompass a more complex network that more accurately reflects biological complexity but is currently 
thought too unwieldy to be useful for testing strategies.  
– There are limitations to basing pathways on current or known biological understanding – bioinformatics can uncover novel 
branches and not yet described biology – but in practice, we need to start somewhere. 
– There is no conceptual difference between pathways based on chemicals and pathways based on drugs – all are a variation 
from normal biological pathways. There are differences in magnitude, however; drug toxicity is generally a concern at doses 
that are similar to biologically active doses, whereas (industrial) chemical exposure is generally at low doses relative to 
biological activity.  
Like other pathway approaches, the purpose of PoT is to first do a better job of predicting human health effects of drug and other 
chemical exposure, to include low dose and consideration of dynamics, and to provide an understanding of the causal linkages 
underlying “normal” biology. PoT can be used to identify predictive biomarkers of off target effects, identify key events, front-
load toxicity prediction in the drug and green chemistry development process, understand toxicity and also safety, and ultimately 
to decrease uncertainty in decision-making. 
 
1.3.2 Hamner Institutes for Health Sciences: pathway-targeted case studies 
In addition to identifying and elucidating critical pathways, assays that measure key steps in these pathways need to be developed 
and validated, and the information from these assays needs to be tied to biologically relevant changes in humans at known or 
estimated chemical concentrations. With analytical tools, toxicogenomic data can be used to inform gene groupings or pathways 
that are modulated by chemical exposure. Analysis of dose-response changes in grouped genes can infer dose-dependent 
transitions in modes-of-action (Andersen et al., 2013). The Hamner Institutes for Health Sciences is developing a series of 
pathway-based case studies with the objective being the simultaneous development of assays along with interpretation and 
extrapolation tools that can be applied to mode-of-action-specific risk and safety estimations, as proof of principle for the 
approach (Andersen et al., 2012). 
 
1.3.2.1 Estrogen Receptor Signaling 
Taking estrogen signaling as a case study for the pathway approach, the Institute for Chemical Safety Sciences at Hamner 
Institutes of Health Sciences is initiating a research program whose goal is to identify a series of well characterized in vitro assays 
that can be used to determine a chemical’s risk of disrupting estrogenic signaling (Andersen, 2012). The approach depends on 
detailed characterization of estrogen signaling, development of refined data interpretation tools, and the creation of prediction and 
in vitro-in vivo extrapolation models. The project uses human Ishikawa adenocarcinoma cells to characterize ER signaling via 
ERα and G-protein coupled estrogen receptor (GPER) and compares this with the rat uterotrophic assay (RUA). An array of data 
is being collected following exposure with strong agonists, including transcriptomics, Ca2+ influx, limited phosphoproteomics and 
ESR1 Chromatin Immunoprecipitation-DNA sequencing (CHIP-seq) data. These data will be analyzed to infer pathway circuitry 
controlling gene expression and the manner in which the circuitry determines phenotypic responses, generating a computational 
systems biology pathway (CSBP) model to describe the dose-response of estrogenic effects in these cells. The in vitro data will be 
compared to detailed pathway analyses of in vivo results from the uterotrophic assay. Finally, the fit-for-purpose in vitro assays 
will then be used to assess the dose response of several estrogenic compounds for a limited set of endpoints and to generate risk 
assessments using this data. 
The goal of this project is to supplement other pathway-based approaches (e.g., the Tox21 effort by EPA, NIH and 
FDA; CAAT’s Human Toxome project) by providing a case study example of the application of the pathway approach directly to 
human health safety assessment for a specific pathway (in this case, chemicals that act through the estrogen receptor). 
Undertaking such a thorough example will provide the basis for and facilitate the same approach being applied to other pathways. 
 
1.3.2.2 PPARα signaling pathway 
The peroxisome proliferator (PP)-activated receptor alpha (PPARα) nuclear receptor is centrally involved in liver cell metabolism. 
PPARα is involved in PP-induced carcinogenicity in rodents, and induces fatty acid metabolizing oxidation systems in response to 
PPs in both rodent and humans (Rao and Reddy, 2004). To map and model the PPARα signaling pathway, the Hamner project 
involves the use of arrays of different ‘omics data from primary human and rat hepatocytes treated with a PPARα-specific ligand 
(Andersen, 2012). Data include microarray-based gene expression data, regulatory interactions inferred from protein-DNA 
transcription factor arrays and published CHIP-on-chip (chromatin immunoprecipitation followed by microarray hybridization) 
results combined to form a picture of PPARα-mediated transcriptional regulation following PPARα activation. This inferred 
response network will serve as the basis for quantitative computational models of the PPARα pathway. 
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1.3.3 Joint Research Centre: SEURAT-1 Workshop on describing mode-of-action in liver toxicity using 
adverse outcome pathways (Oct 24-25, 2012). 
The 2012 workshop was organized by SEURAT-1 (Safety Evaluation Ultimately Replacing Animal Testing) Mode-of-Action 
Working Group and COACH, the project coordination activity. The discussion of this workshop and presentation of the two liver-
specific pathways in Section 2 below sets the stage for the 2013 workshop report “Building Shared Experience to Advance 
Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action,” published elsewhere in this journal 
(Willett et al., 2014).  
SEURAT-1, a FP 7 project co-financed by the European Commission and Cosmetics Europe, is currently the largest 
European research initiative, composed of six research projects that aim to fundamentally change the way we assess the safety of 
chemicals. The goal is to move away from safety assessment relying on animal experiments towards a paradigm based on using 
mechanistic understanding of toxicology to intelligently integrate leading edge computational and in vitro tools into systems that 
support predictive safety assessment. 
The objectives of this expert workshop were to evaluate practical processes and tools for describing and reporting a 
MoA or AOP, based on elaborated examples, and to consider how such MoA knowledge can be practically applied within 
SEURAT-1 projects. The workshop also provided an opportunity to bring MoA and AOP practitioners together for sharing the 
current status of various international activities and to exchange experiences and plans. Various views on MoA/AOP/Tox-
Pathway development were captured with the emphasis being more on the building process itself rather than on the actual content 
of the pathways. 
In addition to those previously mentioned issues that need to be addressed (e.g., the level of detail determines 
usefulness, a consistent terminology is needed, animal data may have limited relevance to human pathways, drugs may or may not 
be a good reference for other chemicals) other topics were highlighted, including the importance of investigating the role of time 
in individual processes; evidence that clinical data show different outcomes for acute and chronic exposure where it remains 
unclear whether the same mechanisms are relevant in these scenarios and how adaptation (compensation and repair) could be 
captured in an AOP. 
Several examples of AOPs in development were presented, including those outlining reproductive toxicity, 
mitochondrial toxicity, carcinogenicity and neurotoxicity. These examples represented diverse approaches – some were based on 
decision-trees (e.g., reproductive toxicity), some focused heavily on MIEs (e.g., mitochondrial toxicity), and metabolism was 
accounted for to greater or lesser degrees. In general, there has been quite a lot of success in using MIEs to identify chemical 
classes and group chemicals, followed by some initial successes in using next steps (e.g., gene expression or other ‘omics finger-
prints) to further identify chemical descriptors and characterize chemical classes. Gene expression and other ‘omics analyses can 
also provide rich data regarding MoAs and temporal relationships between events in a pathway. Improved computational tools are 
needed to facilitate interpretation of ‘omics data in terms of biological pathways, including tools that can consider kinetic, 
dynamic, and homeostatic dimensions.  
The enormous complexity and amount of work that has informed each example was apparent. Yet again, the need for a 
common language was highlighted, as well as the importance of sharing supporting information and pathways as they develop. 
An important observation was that the experimental design and research needed for pathway elucidation is quite different from 
the one that applies AOP knowledge. For example, an AOP intended to simply convey mechanistic understanding will differ from 
one intended to guide hazard identification, which in turn will differ from an AOP that should provide the basis for quantitative 
risk or safety assessment. In order to satisfy more demanding use-cases, such as the development of integrated assessment and 
testing strategies for the prediction of in vivo points-of-departure, quantitative rather than purely qualitative information in an 
AOP is indispensable. One unresolved issue was a divergence of opinion about whether it was useful or necessary to describe the 
sequence of events along the pathway in a linear form.  
Two pathways were presented as prototypes for pathway development: MoA from protein alkylation to liver fibrosis, 
and MoA from Liver X Receptor activation to liver steatosis (Landesmann et al., 2012). These prototype pathways are described 
in more detail in the next section. 
 
 
2 Liver toxicity Modes of Action  
 
2.1 Introduction 
Due to its integral function as the central clearing house of the body for exogenous (and endogenous) chemicals, as well as its 
close proximity to the gut and spleen, the liver is particularly susceptible to toxicity from both parent compounds and metabolites. 
Liver injury is the most common cause for drug failure in clinical trials and for drugs to be withdrawn from the market.  
 
2.2 Liver metabolism 
There are two general forms of metabolism that occur in the liver (and in other tissues), Phase I and Phase II. Phase I metabolism 
primarily increases water solubility of chemicals by oxidation, reduction, hydrolysis, hydration and other, less prominent 
reactions. Oxidation by cytochrome P450 enzymes is the most prevalent Phase I reaction, accounting for approximately 75% of 
all drug metabolism (Guengerich, 2008). Cytochrome P450 enzymes comprise the terminal oxidase component of an electron 
transport chain. Of the 57 members of the cytochrome P450 gene family, the protein products of six are responsible for most drug 
metabolism: P450s 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, and 3A4. Oxidation by P450 enzymes requires cofactors to supply and 
accept electrons (e.g., NAD(P)H) and coenzymes (e.g., cytochrome P450 reductase). P450s are located in the inner membrane of 
the mitochondria or on the endoplasmic reticulum, are present in most tissues (although metabolism of most toxic substances, 
including exogenous chemicals, occurs in the liver) and play a central role in metabolism, including hormone metabolism.  
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In Phase II metabolism, metabolic intermediates (including those generated by Phase I metabolism) are conjugated to small polar 
molecules (e.g., glutathione [GSH], sulfate, glycine, glucuronic acid), by transferases (e.g., UDP-glucuronosyltransferases [UGT], 
N-acetyltransferases [NAT], glutathione S-transferases [GST], sulfotransferases [SULT], acetyl-Co-As) generally to render them 
inert and target them for excretion. Most Phase II reactions occur in the cytosol. 
 
2.3 Liver injury/toxicity 
Due to its central role in metabolism of exogenous substances, the liver is susceptible to chemical damage via many direct and 
indirect mechanisms. Some of these mechanisms include oxidative stress caused by chemicals that interfere with signaling or 
electron transport in mitochondria and modulation of the cytochrome P-450 system, ultimately leading to cellular necrosis or 
apoptosis. Hepatocyte damage can also trigger inflammation (hepatitis) and involvement of the immune system, further 
exacerbating the injury. Acute liver toxicity is generally of one of two types; direct cytotoxicity resulting in necrosis or apoptosis 
or indirect cytotoxicity following interference of the flow of bile (cholestasis), either via circulatory obstruction or by disruption 
of bile metabolism (Tab. 1) (Goodman, 2007; Holt and Ju, 2006). Chronic liver injury can lead to fatty acid accumulation 
(steatosis), cholestasis, hepatitis (including granuloma formation), accumulation of phospholipids (phospholipidosis) and fibrosis. 
If the damage is not reversed, injury can ultimately lead to cirrhosis (a build-up of fibrous scar tissue and regenerative tissue 
nodules causing a loss of liver function) and/or neoplasia. 
 
2.4 Drug induced liver injury 
Drug-induced liver injury (DILI) is a rare but serious health problem; DILI accounts for 50% of acute liver failure incidents and is 
a significant reason for removing drugs from the market. The rare occurrence of DILI (1 in 10,000 to 100,000 treated patients; 
Kaplowitz, 2005) renders it difficult to detect in clinical trials, which highlights the need for a better understanding of underlying 
mechanisms in order to better predict potential occurrence. 
Liver damage caused by drugs has been parsed into two classes: Type A (or intrinsic) damage is the most common 
(80% of drug-induced liver injury) and is related to the pharmacological activity of the drug, is dose-dependent, and can be 
explained and predicted by known biological mechanisms; Type B (or idiosyncratic) is neither predictable nor reproducible, and 
can be dose-independent. Idiosyncratic liver injury is rare and thought to be a result of individually variable susceptibility factors 
and can be classified as allergic or non-allergic (Kaplowitz, 2005). Allergic reactions involve the participation of the adaptive 
immune system and most likely involve a secondary trigger such as increased levels of cytokines due to viral or bacterial 
infection; non-allergenic reactions can have a latency period of several months and be independent of dose. Most frequently it’s 
not the parent drug that is hepatotoxic, but the Phase I metabolite of the drug; more rarely Phase II metabolites are hepatotoxic 
(Au et al., 2011).  
Chemicals produce a wide variety of histologically and clinically-described pathologies which have been characterized 
historically as hepatocellular, cholestatic or mixed (Tab. 2). Hepatocellular injury causes release of aminotransferases (alanine 
[ALT] and aspartate [AST]) and alkaline phosphatase (ALP); however these enzymes are not liver-specific and occur in several 
tissues. ALT is thought to be slightly more liver-specific than AST, and an increase of ALT of three-times the upper level of 
normal (UNL) is considered a sensitive, if not completely specific, marker of hepatocyte injury. In addition, extensive damage 
interferes with the liver’s ability to clear bilirubin from the plasma, causing a rise in plasma bilirubin levels and is a diagnostic 
indicator of impaired liver function (known as “Hy’s law,” after the scientist, Hy Zimmerman, who first made the connection). 
Hy’s Law is informally described as satisfying the following conditions: (a) ALT level more than three times ULN, accompanied 
by (b) total bilirubin level more than twice ULN, and in the absence of any other potential cause of liver impairment (e.g., viral 
hepatitis or preexisting liver disease) (US FDA, 2009). US FDA guidance suggests that a clinical finding of “Hy’s Law” in two or 
more cases indicates a strong potential for DILI, although studies with some drugs suggest this may be too stringent and the 
search for more predictive markers continues (Kaplowitz, 2005). 
 
 
3 Liver toxicity MoAs from the SEURAT-1 project  
 
The SEURAT-1 project is focusing on an integrated approach to model repeat dose toxicity, and hepatoxicity was chosen as the 
first case study to define and describe a MoA to a sufficient extent to facilitate conducting a feasibility study (Landesmann et al., 
2012). These prototypes were developed following the OECD guidance for AOP development, and the methods used to support 
pathway development are described. For these prototypes, there is a large amount of data to support the causal linkages between 
key events, thus in this project, these pathways are described synonymously as AOPs or MoAs. The AOs liver fibrosis and 
steatosis typically result from chronic injury; the respective MIEs were based on SEURAT-1 reference chemicals for these two 
adverse effects. 
 
3.1 Fibrosis: MoA from protein alkylation to liver fibrosis 
Liver fibrosis is the result of a cycle of necrosis/apoptosis and regeneration caused by repeated injury to the liver. An imbalance in 
the degradation and deposition of extracellular matrix during this cycle results in an accumulation of fibrous extracellular matrix 
(ECM) that eventually interferes with normal liver function. The SEURAT fibrosis MoA was delineated using information from 
exposure to allyl alcohol and carbon tetrachloride. 
Briefly (for detail, see Landesmann et al., 2012): the MIE for both chemicals is protein alkylation: allyl alcohol is 
oxidized by alcohol dehydrogenase to acrolein which is highly reactive and readily alkylates proteins; CCl4 is oxidized by the 
cytochrome P450 system to a reactive CCl3 free-radical that alkylates proteins and DNA and causes lipid peroxidation, resulting 
in necrosis. 
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Alkylation of liver proteins and lipid peroxidation accompanied by oxidative stress triggers apoptotic cell death (Fig. 4). 
Cell death releases reactive oxygen species (ROS), cytokines and chemokines that trigger oxidative stress, elicit inflammation and 
activate Kupffer cells (KCs), hepatic stellate cells (HSCs) and platelets. KCs and HSCs are also activated by phagocytosing 
apoptotic cell remnants. 
Activated KCs generate ROS and counterbalancing nitrous oxides, inflammatory mediators including cytokines and 
chemokines, as well as a number of cytokines that induce HSC proliferation. KCs, platelets, and sinusoidal endothelial cells also 
release TGF-β1, which is the most important and potent fibrogenic cytokine. As HSCs become activated they also express TGF-
β1. TGF-β1 in turn further activates HSCs, simulates ECM synthesis and suppresses ECM degradation. This prolonged phase of 
HSC activation is called the “perpetuation phase”, during which HSCs proliferate and release chemokines that enhance 
inflammation.  
Overlapping this process is ongoing oxidative stress associated with an increase in ROS generated by KCs, HSCs and 
inflammatory cells. Increased ROS further induce fibrillar ECM production. Due to the increase in ROS and chemokines, a state 
of chronic inflammation is established and facilitates progression of fibrosis. Following the induction of macrophages, other 
inflammatory cells such as T, dendritic and natural killer cells are recruited into the process. As HSCs are activated, they increase 
fibrosis in two ways; by cellular proliferation and by increasing ECM production per cell. Stimulated HSCs respond to increased 
EMC and further differentiate into contractile myofibroblasts, which are the primary collagen producing cells.  
Additional sources of ECM include bone marrow (which probably gives rise to circulating fibrocytes), portal 
fibroblasts, EMT (epithelial-mesenchymal cell transition) from hepatocytes and cholangiocytes and MET (mesenchymal-to-
epithelial transition), in which mesenchymal cells give rise to epithelium.  
Several other signaling pathways influence HSC activation, including adipokines from adipose tissue and infiltrating 
macrophages. Liver damage stimulates the local neuroendocrine system which also has the effect of accelerating fibrosis.  
Fibrogenesis is a general mechanism that can be induced in may tissue types (e.g., lung, kidney, and lymphoid tissue) – 
any tissue where chronic injury involves a cycle of tissue destruction, inflammation and repair. 
 
3.2 Steatosis: MoA from Liver X Receptor activation to liver steatosis 
Steatosis, also known as fatty liver, is the result of an imbalance in triglyceride metabolism and is characterized by the 
accumulation of lipid within hepatocytes. While steatosis itself is reversible and does not necessarily disrupt liver function (it is 
not necessarily an adverse outcome), it can be a precursor to liver disease such as non-alcoholic fatty liver disease.  
 Briefly: one MIE leading to steatosis could be interference with nuclear receptors involved in homeostasis of fatty acid 
metabolism (Fig. 5). Chemical substances can bind nuclear receptors such as the Liver X receptor (LXR), corticosteroid receptors, 
retinoic acid receptor (RAR), retinoid X receptor (RXR), Vitamin D receptor, peroxisome proliferator activated receptors alpha 
and gamma (e.g., PPARα, PPARγ), pregnane X receptor (PXR), aryl hydrocarbon receptor (AhR), and estrogen receptors (ER) 
and might perturb normal homeostasis of fatty acid metabolism.  
 Binding to LXR causes an induction of transcription factors leading to de novo fatty acid and tryglyceride synthesis as 
well as an influx of fat from peripheral tissues to the liver. There are two isoforms of LXR in mammals (LXRα and LXRβ) that 
form heterodimers with RXR to bind LXR response elements in the promoters of a number of genes involved in fatty acid 
metabolism. LXRα is expressed in several tissues but predominantly in liver, while LXRβ is ubiquitously expressed, and LXRα 
knock-out mice do not develop steatosis, indicating that LXRα may be more involved in liver-specific activities including 
steatosis. LXRs can also be regulated by other nuclear receptors, e.g., the LXRα promoter is regulated by PPARα and insulin.  
 Genes regulated by LXR/RXR include fatty acid synthase, apolipoprotein E, lipoprotein lipase, fatty acid uptake 
transporter, as well as its own promoter and other regulatory proteins such as the carbohydrate response element binding protein 
(ChREBP), and sterol response element binding protein (SREBP-1c). In turn, ChREBP activates several enzymes involved in 
glycolysis and lipogenesis including acetyl-CoA-carboxylase (ACC) and fatty acid synthase (FAS). SREBP-1c induces 
expression of the genes encoding ACC and FAS. LXR activation also causes induces expression of stearoyl-CoA-desaturase 1 
(SCD1) which is involved in triglyceride accumulation in hepatocytes by an incompletely understood mechanism. In liver cells, 
the fatty acid translocase (CD36) gene is a target of activated LXR. CD36 mediates uptake and transport of long chain fatty acids 
in many cell types.  
 The result of activation of genes and enzymes involved in triglyceride synthesis and fatty-acid uptake in the liver is 
accumulation of large amount of fatty acid in hepatocytes. As a result, intracellular hepatic changes include displacement of the 
nucleus and cytoplasm possibly accompanied by mitochondrial toxicity and endoplasmic reticulum stress. With continued injury, 
steatosis can progress to fibrosis and cirrhosis. As indicated, LXR binding is one of several interrelated MIEs that can lead to 
steatosis.  
 
 
4 Summary 
 
Recent global activities have been focused on initiating a paradigm shift in the way in which drug and chemical toxicity 
characterizations are conducted; with one major area being the definition and use of pathway-based assessments. To this end, 
several overlapping and related frameworks have been proposed over time, including modes of action, adverse outcome pathways, 
toxicity pathways, and pathways of toxicity. This review provides an overview of the history of pathway development, use of 
example AOPs, and several ongoing activities associated with pathway development. Two prototype pathways in liver toxicity are 
presented in more detail that are being developed as part of the SEURAT project and that were the subject of a 2013 workshop 
and report published elsewhere in this journal, “Building Shared Experience to Advance Practical Application of Pathway-Based 
Toxicology: Liver Toxicity Mode-of-Action,” (Willett, et al., 2014). Pathway activities are converging on a set of definitions and 
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principles to demonstrate confidence – principles based on Bradford-Hill criteria as first applied to Mode of Action frameworks 
(Boobis et al. 2006, 2008; Meek et al., 2014) – that are being formalized in guidance developed by the OECD (2013) and by 
others,11 in an effort to globalize and harmonize pathway development.  
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Tab. 1: Use of pathway-related terms 
 
Adverse Outcome 
Pathway 
Ankley et al., 2010 “A conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular initiating event 
(e.g., a molecular interaction between a xenobiotic and a specific biomolecule) and an adverse outcome at a biological level of 
organization relevant to risk assessment.” The AOP is seen as encompassing both the MoA and Toxicity Pathway. 
OECD, 2012 “An adverse outcome pathway (AOP) is the sequence of events from the chemical structure of a target chemical or group of 
similar chemicals through the molecular initiating event to an in vivo outcome of interest. Each AOP represents the existing 
knowledge concerning the linkage(s) between a molecular 
initiating event, intermediate events and an adverse outcome at the individual or population level.” 
OECD, 2013 “An AOP is a sequence of events from the exposure of an individual or population to a chemical substance through a final 
adverse (toxic) effect at the individual level (for human health) or population level (for ecotoxicological endpoints). The key 
events in an AOP should be definable and make sense from a physiological and biochemical perspective. AOPs incorporate the 
toxicity pathway and mode of action for an adverse effect. AOPs may be related to other mechanisms and pathways as well as 
to detoxification routes.”  
Meek et al., 2014 The new MoA framework describes MoA as is conceptually similar to an Adverse Outcome Pathway except that MoA is not 
necessarily adverse (see below under MoA). 
Intermediate Event Ankley et al., 2010 Refers to to “intermediate endpoints” as the endpoints linking adverse outcomes to molecular initiating events. 
OECD, 2013 Biological events that lie “between the molecular initiating event and the apical outcome” from which the Key Events are 
identified. 
Key Event Boobis et al., 2008 “Key events are those events that are critical to the induction of the toxicological response as hypothesized in the postulated 
MOA and are also measurable.”  
OECD, 2008 “A key event is an empirically observed precursor step that is itself a necessary element of the mode of action or is a biologically 
based marker for such an element.” 
Meek et al., 2014 “An empirically observable step or its marker, which is a necessary element of the mode of action critical to the outcome (i.e., 
necessary, but not necessarily sufficient in its own right); key events are measurable and reproducible.” 
Mechanism of Action EPA 2009 “Mechanism of action implies a more detailed understanding and description of events, often at the molecular level, than is 
meant by mode of action.” 
ECETOC, 2007 
 
“A complete and detailed understanding of each and every step in the sequence of events that leads to a toxic outcome.” 
Mode of Action (MoA) ECETOC, 2007 
 
‘‘A common set of biochemical, physiological, or behavioral responses that characterize an adverse biological response where 
major, but not necessarily all, linkages between a direct initiating event and an adverse outcome are understood.” 
EPA, 2009 “A sequence of key events and processes, starting with interaction of an agent with a cell, proceeding through operational and 
anatomical changes, and resulting in an adverse health effect.” 
Meek et al., 2014 “A biologically plausible series of key events leading to an effect.” 
Molecular Initiating 
Event 
Ankley et al., 2010 “A molecular interaction between a xenobiotic and a specific biomolecule.” 
OECD, 2011  The initial point of chemical-biological interaction within the organism that starts the pathway.  
Pathway of Toxicity Kleensang et al., 2014  Working definition: “a molecular definition of cellular processes shown to mediate adverse outcomes of toxicants” 
Toxicity Pathway NRC, 2007 “A cellular response pathway that, when sufficiently perturbed, is expected to result in adverse health effect.” This definition 
does not explicitly include the adverse effect itself. 
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Tab. 2: Types of toxic liver injury 
 
Injury type Description Implicated drugs or chemicals 
Necrosis Direct cell death, often restricted to particular zones of the 
liver (zonal necrosis). Associated with high alanine 
aminotransferase [ALT]. 
Paracetamol, carbon tetrachloride, 
acetominophen (zonal), methyldopa 
(non-zonal) 
Hepatitis Cytotoxicity induced inflammation. Three types: 1) 
histologically similar to viral hepatitis (most common); 2) 
focal or non-specific, where cell death associated with 
lymphocytic infiltration is in scattered foci, and 3) chronic 
hepatitis 
“Viral” hepatitis: halothane, isoniazid, 
phenytoin 
Focal: aspirin 
Chronic: methyldopa, diclofenac 
Cholestasis impairment of bile flow, results in jaundice, can be 
associated with inflammation 
Non-inflammatory: Oral contraceptive 
pills, anabolic steroids, androgens 
Inflammatory: Allopurinol, co-amoxiclav, 
carbamazepine 
Ductal: Chlorpromazine, flucloxacillin 
Steatosis Also known as fatty liver, hepatotoxicity that changes the 
way liver cells process fat (triglycerides) resulting in 
accumulation of fat deposits, either in small droplet 
(microvesicular) or large droplet (macrovesicular) deposits 
Microvesicular: aspirin, ketoprofen, 
tetracycline (especially if expired) 
Macrovesicular: acetaminophen, 
methotrexate 
Granuloma An inflammatory response resulting in a localized collection 
of macrophages. Possibly related to systemic toxicity, 
idiosyncratic, or asymptomatic 
Allopurinol, phenytoin, isoniazid, quinine, 
penicillin, quinidine 
Neoplasms Both benign and malignant neoplasms have been found in 
various hepatic cell types including hepatocytes, biliary 
epithelial cells, and vascular endothelial cells. Common 
benign neoplasms are hepatocellular adenoma and bile duct 
cysts. Common malignant neoplasms are hepatocellular 
carcinoma and angiosarcoma.  
Vinyl chloride, combined oral 
contraceptive pill, anabolic steroid, 
arsenic, thorotrast 
Vascular lesions Damage to the vascular endothelium Chemotherapeutic agents, anabolic 
steroids, oral contraceptives 
Fibrosis Liver fibrosis is a reversible wound healing response to a 
variety of chronic injuries including toxic injury from 
chemicals. Pathogenic fibrosis typically results from chronic 
injury with sustained production of growth factors and 
fibrogenic cytokines in which inflammation, tissue 
destruction, and repair processes occur simultaneously 
Ethanol, Carbon Tetrachloride, 
Methotrexate, Allyl Alcohol,  
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Figure legends 
 
Fig. 1: An Adverse Outcome Pathway is a biological map from the molecular initiating event through the 
resulting adverse outcome that encompasses both mechanism and mode-of-action 
Adapted from Ankley et al. (2010) and OECD (2013). 
 
Fig. 2: Flow diagram of the pathways associated with skin sensitization  
Delineated below the diagram are the pathway subtypes: Toxicity Pathway as defined by the 2007 NRC report, Mode-
of-Action Pathway as discussed in the WHO/IPCS guidance and Adverse Outcome Pathway as defined by Ankley, et 
al. (2010). Adapted from OECD (2012). 
 
Fig. 3: Outline of AOP for estrogen receptor-mediated reproductive toxicity  
Adapted from OECD (2011).  
 
Fig. 4: Flow diagram of the fibrosis MoA.  
Adapted from Landesmann et al., 2012. 
 
Fig. 5: Flow diagram of MoA from LXR activation to liver steatosis 
Adapted from Landesmann et al., 2012. 
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